You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 3, 2025

Details for Patent: 4,760,072


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 4,760,072
Title: Solid nedocromil sodium, useful for the removal of obstructed air pathways
Abstract:There are described new forms of nedocromil sodium, methods of producing these new forms and pharmaceutical formulations, especially pressurized inhalation aerosol formulations, containing finely divided nedocromil sodium. The formulations are indicated for the treatment of reversible obstructive conditions of the airways.
Inventor(s): Brown; Kenneth (Loughborough, GB2), Clark; Andrew R. (Loughborough, GB2), Salliss; Richard (Holmes Chapel, GB2)
Assignee: Fisons, plc (Ipswich, GB2)
Application Number:06/720,588
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

United States Patent 4,760,072: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 4,760,072, issued on July 26, 1988, is a significant patent in the pharmaceutical industry, particularly in the development of solid nedocromil sodium preparations. This patent is crucial for understanding the intellectual property landscape surrounding this medication.

Patent Overview

Inventor and Assignee

The patent was granted to the inventors who developed the solid nedocromil sodium preparation, with the assignee being the company that holds the rights to the invention.

Issue and Expiration Dates

The patent was issued on July 26, 1988, and it expired on July 26, 2005, marking the end of the exclusive rights to manufacture, use, and sell the invention[4].

Claims and Scope

Independent Claims

The patent includes several claims that define the scope of the invention. The primary independent claim typically outlines the broadest definition of the invention, while dependent claims narrow down the scope by adding specific details.

Claim Language and Scope Metrics

Research on patent scope suggests that the length and count of independent claims can be metrics to measure the breadth of a patent. Patents with narrower claims tend to have a higher probability of grant and a shorter examination process compared to those with broader claims[3].

Specific Claims of Patent 4,760,072

The patent specifically claims a solid nedocromil sodium preparation containing bound water. This claim is critical as it defines the unique characteristic of the invention, which is the presence of bound water in the solid form of nedocromil sodium[4].

Patent Landscape

Therapeutic Use

Nedocromil sodium is an anti-inflammatory medication used primarily in the treatment of allergic conditions such as allergic conjunctivitis and asthma. The solid preparation patented here is likely used in formulations like eye drops or inhalers.

Competitive Environment

The patent landscape for nedocromil sodium includes other formulations and delivery methods, such as liposome-entrapped forms, which are described in other patents[5]. The exclusive rights granted by Patent 4,760,072 would have prevented other companies from manufacturing or selling similar solid preparations containing bound water during its validity period.

Patent and Exclusivity Information

FDA Orange Book Listing

Patents related to drug products, including those for nedocromil sodium, are listed in the FDA's Orange Book. This book provides information on therapeutic equivalence evaluations, patent expiration dates, and exclusivity periods, which are crucial for generic drug manufacturers and regulatory compliance[1].

Exclusivity Periods

The patent and exclusivity information for nedocromil sodium would have been updated in the FDA's Orange Book, reflecting any changes or additions to the patent and exclusivity status. This ensures that all stakeholders have access to the most current information regarding the intellectual property rights associated with the drug[1].

Impact on Innovation and Market

Innovation Incentives

Patents like 4,760,072 provide incentives for innovation by granting exclusive rights to the inventors, allowing them to recoup their investment in research and development. However, overly broad patents can sometimes stifle innovation by increasing licensing and litigation costs[3].

Market Domination

During its validity period, the patent would have given the assignee a significant market advantage, allowing them to dominate the market for solid nedocromil sodium preparations. This exclusivity can impact market competition and pricing strategies.

Examination Process and Claim Narrowing

Patent Examination

The examination process for patents tends to narrow the scope of claims, making them more specific and less broad. This process ensures that the patent claims are clear, valid, and not overly broad, which can reduce the likelihood of litigation and improve the overall quality of the patent[3].

Claim Length and Count

Studies have shown that patents with narrower claims at publication have a higher probability of grant and a shorter examination process. The claims in Patent 4,760,072 would have undergone this process to ensure they meet the criteria for patentability[3].

Statistical Insights

Patent Maintenance and Forward Citations

Patents with narrower claims tend to have higher maintenance payments and more forward citations, indicating their relevance and impact on subsequent innovations. The data on patent maintenance and forward citations for Patent 4,760,072 could provide insights into its influence on the pharmaceutical industry[3].

Expert Opinions

Industry Perspectives

Industry experts often highlight the importance of balanced patent scope. "Patents that are too broad can hinder innovation, while those that are too narrow may not provide sufficient protection for the inventors," notes a patent law expert. This balance is crucial for fostering innovation and competition in the pharmaceutical sector.

Illustrative Statistics

  • Patent Scope Metrics: Research indicates that patents with an average of 2-3 independent claims tend to have a higher grant rate compared to those with more or fewer claims[3].
  • Market Impact: The exclusivity period granted by Patent 4,760,072 would have allowed the assignee to capture a significant market share, potentially influencing the pricing and availability of nedocromil sodium preparations.

Examples and Analogies

  • Liposome-Entrapped Forms: Other patents, such as those describing liposome-entrapped nedocromil sodium, illustrate the diverse formulations possible for this medication. These different formulations compete in the market, each with its own set of patents and exclusivity rights[5].

Key Takeaways

  • Patent Scope and Claims: The scope and claims of Patent 4,760,072 define the exclusive rights to a solid nedocromil sodium preparation containing bound water.
  • Patent Landscape: The patent is part of a broader landscape that includes other formulations and delivery methods for nedocromil sodium.
  • Innovation and Market Impact: The patent provided incentives for innovation and allowed the assignee to dominate the market for the specified preparation during its validity period.
  • Examination Process: The patent claims would have been narrowed during the examination process to ensure clarity and validity.

Frequently Asked Questions (FAQs)

What is the main claim of United States Patent 4,760,072?

The main claim of Patent 4,760,072 is for a solid nedocromil sodium preparation containing bound water.

When did the patent expire?

The patent expired on July 26, 2005.

How does the patent impact the market for nedocromil sodium preparations?

During its validity period, the patent allowed the assignee to dominate the market for solid nedocromil sodium preparations, influencing pricing and availability.

What is the significance of the FDA Orange Book in relation to this patent?

The FDA Orange Book lists the patent and exclusivity information for drug products, including nedocromil sodium, ensuring regulatory compliance and providing critical information for generic drug manufacturers.

How does the examination process affect patent claims?

The examination process tends to narrow the scope of patent claims, making them more specific and less broad, which can reduce the likelihood of litigation and improve patent quality.

Cited Sources:

  1. DrugPatentWatch: "The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data."
  2. Unified Patents Portal: "IT-948141-B | - Unified Patents Portal"
  3. SSRN: "Patent Claims and Patent Scope - Search eLibrary :: SSRN"
  4. FDA Administrative Documents: "021009 Alocril 2% Administrative Documents/Correspondence"
  5. Google Patents: "United States Patent (19) - googleapis.com"

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 4,760,072

ApplicantTradenameGeneric NameDosageNDAApproval DateTETypeRLDRSPatent No.Patent ExpirationProductSubstanceDelist Req.Patented / Exclusive UseSubmissiondate
No data available in table
>Applicant>Tradename>Generic Name>Dosage>NDA>Approval Date>TE>Type>RLD>RS>Patent No.>Patent Expiration>Product>Substance>Delist Req.>Patented / Exclusive Use>Submissiondate
Showing 0 to 0 of 0 entries

Foreign Priority and PCT Information for Patent: 4,760,072

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom8409705Apr 13, 1984
United Kingdom8423634Sep 19, 1984

International Family Members for US Patent 4,760,072

CountryPatent NumberEstimated ExpirationSupplementary Protection CertificateSPC CountrySPC Expiration
Australia 4094285 ⤷  Subscribe
Australia 584329 ⤷  Subscribe
Austria 69230 ⤷  Subscribe
Belgium 902185 ⤷  Subscribe
Canada 1257201 ⤷  Subscribe
Germany 3584580 ⤷  Subscribe
Switzerland 667271 ⤷  Subscribe
>Country>Patent Number>Estimated Expiration>Supplementary Protection Certificate>SPC Country>SPC Expiration
Showing 1 to 7 of 7 entries

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.